HUE065075T2 - Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére - Google Patents

Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére

Info

Publication number
HUE065075T2
HUE065075T2 HUE20804279A HUE20804279A HUE065075T2 HU E065075 T2 HUE065075 T2 HU E065075T2 HU E20804279 A HUE20804279 A HU E20804279A HU E20804279 A HUE20804279 A HU E20804279A HU E065075 T2 HUE065075 T2 HU E065075T2
Authority
HU
Hungary
Prior art keywords
prevention
treatment
antigenic peptides
cell malignancy
malignancy
Prior art date
Application number
HUE20804279A
Other languages
English (en)
Hungarian (hu)
Inventor
Laurent Chene
Francesco Strozzi
Joao Gamelas Magalhaes
Guillaume Kulakowski
Original Assignee
Enterome S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome S A filed Critical Enterome S A
Publication of HUE065075T2 publication Critical patent/HUE065075T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE20804279A 2019-11-15 2020-11-13 Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére HUE065075T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306475 2019-11-15
EP2020079257 2020-10-16

Publications (1)

Publication Number Publication Date
HUE065075T2 true HUE065075T2 (hu) 2024-04-28

Family

ID=75911928

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE20804279A HUE065075T2 (hu) 2019-11-15 2020-11-13 Antigén peptidek B-sejtes malignitás megelõzésére és kezelésére

Country Status (19)

Country Link
US (2) US11759508B2 (enExample)
EP (2) EP4357356A3 (enExample)
JP (1) JP2023501204A (enExample)
CN (1) CN114746112A (enExample)
AU (1) AU2020384926B2 (enExample)
BR (1) BR112022009100A2 (enExample)
CA (2) CA3153470A1 (enExample)
DK (1) DK4021487T5 (enExample)
ES (1) ES2971929T3 (enExample)
FI (1) FI4021487T3 (enExample)
HR (1) HRP20240116T1 (enExample)
HU (1) HUE065075T2 (enExample)
LT (1) LT4021487T (enExample)
MX (1) MX2022005704A (enExample)
PL (1) PL4021487T3 (enExample)
RS (1) RS65262B1 (enExample)
SI (1) SI4021487T1 (enExample)
SM (1) SMT202400048T1 (enExample)
WO (1) WO2021094562A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
IL302345B2 (en) 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
DK3773689T5 (da) 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
JP2025081784A (ja) * 2022-03-01 2025-05-28 ｂｉｔＢｉｏｍｅ株式会社 アミノ酸残基配列を同定するための方法，プログラム及び記録媒体
US20260041748A1 (en) * 2022-07-29 2026-02-12 Lg Chem, Ltd. Recombinant fusion protein for antigen delivery and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
AU2017254477A1 (en) * 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
CN106008695A (zh) * 2016-06-19 2016-10-12 苏州普罗达生物科技有限公司 一种关于cd19免疫原多肽及其用途
IL302345B2 (en) * 2016-10-07 2024-12-01 Enterome S A Immunogenic compounds for cancer therapy
EP3679065A4 (en) * 2017-09-06 2021-05-19 California Institute of Technology SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)
JP7232825B2 (ja) * 2017-10-09 2023-03-03 エンテローム エスエー 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体
DK3773689T5 (da) * 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
WO2020072700A1 (en) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines

Also Published As

Publication number Publication date
DK4021487T5 (da) 2024-07-29
EP4357356A2 (en) 2024-04-24
US20220323561A1 (en) 2022-10-13
HRP20240116T1 (hr) 2024-04-12
US11759508B2 (en) 2023-09-19
FI4021487T3 (fi) 2024-02-06
JP2023501204A (ja) 2023-01-18
SMT202400048T1 (it) 2024-03-13
ES2971929T3 (es) 2024-06-10
EP4357356A3 (en) 2024-07-31
PL4021487T3 (pl) 2024-04-15
CA3153470A1 (en) 2021-05-20
CN114746112A (zh) 2022-07-12
CA3290212A1 (en) 2026-03-02
RS65262B1 (sr) 2024-03-29
DK4021487T3 (da) 2024-02-12
AU2020384926B2 (en) 2025-09-18
SI4021487T1 (sl) 2024-03-29
EP4021487B1 (en) 2023-12-27
AU2020384926A1 (en) 2022-04-28
EP4021487A2 (en) 2022-07-06
WO2021094562A2 (en) 2021-05-20
WO2021094562A3 (en) 2021-09-30
MX2022005704A (es) 2022-06-08
US20240033335A1 (en) 2024-02-01
BR112022009100A2 (pt) 2022-07-26
LT4021487T (lt) 2024-02-12

Similar Documents

Publication Publication Date Title
PL4021487T3 (pl) Peptydy antygenowe do zapobiegania i leczenia nowotworów złośliwych wywodzących się z limfocytów b
SI3773689T1 (sl) Antigenski peptidi za preprečevanje in zdravljenje raka
IL279347A (en) Gremlin-1 antagonist for cancer prevention and treatment
GB201804514D0 (en) Treatment of pyroptosis
SG11202006160RA (en) Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer
IL290656A (en) Lorbinectadine in the treatment of malignant mesothelioma
IL285807A (en) Immunotherapy for cancer treatment
GB201919428D0 (en) Immunotherapeutic treatment of cancer
IL284237A (en) Imaging and treatment of tumors expressing somastatin receptor
IL280468A (en) Secondary vaccine particles for cancer treatment
GB201804515D0 (en) Treatment of necroptosis
IL290983A (en) Treatment methods
IL281997A (en) Combined treatment for the treatment of uveal melanoma
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
IL285458A (en) Combined therapy for the treatment of b-cell malignancies
IL287538A (en) Preparations and methods for the treatment of cancer
PT4021487T (pt) Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b
GB201918853D0 (en) Methods of treatment
IL271727A (en) Method of treatment and their dosage forms
GB201810635D0 (en) Peptides and cancer treatment
IL288433A (en) Peroxidase-3 activation and immunotherapy for cancer treatment
IL280262A (en) Compositions and methods for treating cancer
GB201918815D0 (en) Treatment of cancer
GB201917493D0 (en) methods for the treatment of uveal melanoma
IL271738A (en) Tumor treatment device